Dose-response relationship and time-varying risks of ischemic stroke of quetiapine, olanzapine, haloperidol, and chlorpromazine compared with risperidone.

(Mean PDD, mean Prescribed Daily Dose) *Adjusted for age, gender, presence or absence of dementia (F00-F03, G30, G31.8), depression (F32–33, F34.1, F41.2), dyslipidemia (E78.0), coronary heart disease (I21-I25), COPD (J40-J44, J47), and the use of antidepressants, benzodiazepine, anticoagulants, or antithrombotic agents during the follow-up period. The estimated HRs were finally accepted as the SMR weighted and multivariable adjusted HR after exclusion of the patients whose propensity score is > 99.99 in quetiapine, < 0.05 in olanzapine, >0.90 in haloperidol, and < 0.05 in chlorpromazine †Could not be estimated. ‡P for trend was calculated using the likelihood ratio test. §Short- and long-term periods were distinguished by the cross-point using a log-log survival curve. Dose-response relationship and time-varying risks of ischemic stroke of quetiapine, olanzapine, haloperidol, and chlorpromazine compared with risperidone.